DELTICOM-AG
It’s buzzing on our roads and motorways. In the first nine months of 2015, there were almost 18% more trucks and commercial vehicles registered in the UK than last year.* In light of these figures, it is worth doing some forward planning and invest wisely. In the UK, the number of road traffic accidents leading to personal injury involving goods vehicles rose in 2014 by 6% in comparison to the previous year.** New tyres can make an absolutely critical contribution to safe mobility.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151126005106/en/
That’s why safety experts advise transport companies and business people who run a small fleet to service their vehicles intensively. Not only does this contribute to increased working life, it also makes an important contribution to road safety. During long, dark European winters with constantly changing weather conditions, having perfect grip increases the mobility of goods transporters and businesses by a significant multiple. “It’s worth investing in fresh tyres , not only when they’re worn, or you have to change because of the season. Very often, every millimetre counts, such as in tricky traffic situations. With new tyres , both driver and business owner are well equipped. Over the last few years, we have specialised in supplying a wide range of complete winter tyres size 17.5”, as these tyres, in particular, cover the whole spectrum of small fleet operators. Business people can count on our online car tyre shops , with excellent availability of 17.5” tyres in all price/performance categories” , says Andreas Wilmsmeier, Key-Account Manager Truck and Commercial Tyres EU at Delticom . He continues: “Our customers benefit from a wide variety of high-quality tyres. More and more transport experts are on the road in the best possible way with our own brand Goodride. Goodride truck tyres are characterised by a high level of reliability and economy”.
At the Delticom online stores for dealers and garages attractive packages are offered to all kind of businesses, no matter if small or large. With a winter discount promotion in December the online tyre dealer supports the safety of its customers. For each purchased truck tyre 10 euro discount will be granted per at the online shops for professional customers in Germany , Austria , Switzerland , France , Italy , Spain and the Netherlands (in Switzerland 10 CHF). The winter discount promotion starts at 1st of December and ends on the 31st of December 2015.
Buying tyres online provide numerous benefits: the stores are “open all hours” - 365 days a year, 24/7, thus saving that valuable resource - time. In addition, business owners can increase efficiency by benefitting from low-cost deals all year round. The truck / commercial vehicle team at Delticom can also offer personal advice if required. Within the UK, the tyres are generally dispatched in 2 - 4 days.
* Source: www.smmt.co.uk
** Source: www.gov.uk
Tyres for trucks, light trucks and commercial vehicles you can find in the online shops for:
- Dealers: www.yourtyres.co.uk , www.autoreifenonline.de , www.autoreifenonline.at , www.autoreifenonline.ch , www.pneus-auto.fr , www.pneumatici123.it , www.neumaticos123.com , www.porbanden.nl
- Fleet clients: www.fleettyres24.co.uk , www.flotten24.de , www.flotten24.at , www.flotten24.ch , www.flotte24.fr , www.flotta24.it , www.fleet24.nl
Truck tyres also available at the online shops for consumers : www.mytyres.co.uk/Truck-Tyres , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch/LKW-Reifen.html , www.123pneus.fr/pneus_camion , www.gommadiretto.it/Pneumatici_autocarri , www.neumaticos-online.es/Neumaticos_camiones , www.autobandenmarkt.nl/Vrachtwagenbanden
Tyre tests: www.tyretests.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005106/en/
Contact:
Delticom AG
Susanne Kindor-d’Unienville
T: +49 511 93634852
E-Mail:
susanne.kindor@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom